Evidence for research over the past decade shows that epigenetic regulation mechanisms
run through the development and prognosis of tumors. Therefore, small molecular …

Bacteria are rich in a wide variety of secondary metabolites, such as pigments, alkaloids,
antibiotics, and others. These bioactive microbial products serve a great application in …

Abstract Background Diffuse midline gliomas (DMGs), including diffuse intrinsic pontine
gliomas (DIPGs), have a dismal prognosis, with less than 2% surviving 5 years …

This multicenter, prospective phase IIb trial evaluating the efficacy and safety of tucidinostat
(HBI‐8000) in patients with relapsed or refractory (R/R) adult T‐cell leukemia/lymphoma …

Peripheral T-cell lymphomas (PTCLs) are a group of highly aggressive malignancies with
generally poor prognoses, and the first-line chemotherapy of PTCL has limited efficacy …

Systemic sclerosis (SSc) is a rare autoimmune disorder characterised by skin fibrosis that
often also affects internal organs, eventually resulting in mortality. Although management of …

The regulation of gene transcription by epigenetic modifications is closely related to many
important life processes and is a hot research topic in the post-genomic era. Since the …

T-cell lymphoma is a rare hematologic malignancy with an incidence rate between 10% and
20% of that of non-Hodgkin lymphomas. Patients with peripheral T-cell lymphoma (PTCL) …

Tucidinostat (formerly known as chidamide) is an orally available, novel benzamide class of
histone deacetylase (HDAC) inhibitor that selectively blocks class I and class IIb HDAC. This …

Abstract Objective HBI-8000 (tucidinostat) is a novel, oral histone deacetylase inhibitor that
selectivity inhibits Class I (histone deacetylase 1, 2, 3) and Class II (histone deacetylase 10) …